Apomorphine - Chiesi

Drug Profile

Apomorphine - Chiesi

Alternative Names: Apofin; Apomorphine hydrochloride - Chiesi; CHF 1526

Latest Information Update: 25 Jan 2011

Price : $50

At a glance

  • Originator Chiesi
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 14 Aug 2006 No development reported - Clinical-Phase-Unknown for Parkinson's disease in Italy (Sublingual)
  • 05 Sep 2000 Investigation in Parkinson's disease in Italy (Sublingual)
  • 15 Jun 2000 Launched for Parkinson's disease in Italy (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top